Compositions and methods for treating clostridium difficile-associated diseases

A clostridium difficile and composition technology, applied in the field of antibodies or antigenic fragments thereof, isolated polypeptides, and vectors containing the nucleic acid molecule, can solve the increased morbidity and mortality of Clostridium difficile-related diseases, prolonged Hospitalization time, additional medical expenses, etc.

Inactive Publication Date: 2016-06-22
NAT INST OF HEALTH REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clostridium difficile-associated disease results in additional medical costs and prolonged hospital stays
Significantly i...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating clostridium difficile-associated diseases
  • Compositions and methods for treating clostridium difficile-associated diseases
  • Compositions and methods for treating clostridium difficile-associated diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0039] The present invention relates to a novel polypeptide comprising the receptor binding domain (RBD) of Clostridium difficile (Cd) toxin A (tcdA). Unexpectedly, such polypeptides, especially when expressed in lipidated form, are highly immunogenic and capable of inducing immunity against Cd challenge in animal models.

[0040] Polypeptides comprising one or more CdtcdA functional domains, and nucleic acids encoding the polypeptides are described below.

[0041] An exemplary polypeptide comprises a C-terminal portion of tcdA that includes the receptor binding domain (RBD) of tcdA, ie, tcdA-RBD or RBD. Listed below are the nucleic acid sequence (SEQ ID NO: 1) encoding tcdA-RBD and the amino acid sequence (SEQ ID NO: 2) of tcdA-RBD. The putative receptor binding region within the RBD is shown in SEQ ID NO: 2 as underlined.

[0042] tcdA-RBD nucleic acid sequence (SEQ ID NO: 1)

[0043] TTTAATAGCGAGAATGAACTGGATCGTGATCATCTGGGCTTCAAAATCATCGATAATAAAACCTATTATTATGATGAAGATAGCAAAC...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides compositions and methods for treating clostridium difficile-associated diseases. Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of Clostridium difficile (Cd), nucleic acids encoding the polypeptides, and methods of using the polypeptides and nucleic acids.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application Serial No. 61 / 782,390, filed March 14, 2013, the entire contents of which are incorporated herein by reference. Background technique [0003] Clostridium difficile (Cd) is an emerging pathogen causing opportunistic infections in hospitals and is the main cause of human antibiotic-associated diseases such as pseudomembranous colitis and diarrhea. [0004] The main pathogenic effect of Clostridium difficile is through two large protein toxins, toxin A (tcdA) and toxin B (tcdB), which destroy intestinal epithelial cells. tcdA and tcdB, are large protein toxins (250 to 308 kDa) with multiple functional domains. Early in the pathogenic process, the receptor-binding domain (RBD) of Clostridium difficile (Cd) first binds carbohydrates located on the surface of colonic epithelial cells. tcdA and / or tcdB enter cells through receptor-mediated endocytosis and destroy ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/33A61K39/08A61K39/39A61P31/04A61P37/04C07K19/00C12N15/31G01N33/569
CPCA61K39/08A61K39/39A61K2039/543A61K2039/55544A61K2039/55566A61P31/04A61P37/04C07K14/33C07K2319/40C12N2799/026G01N33/56911G01N2333/33
Inventor 庄再成黄瑞鑫冷治湘
Owner NAT INST OF HEALTH REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap